Agenus's Botensilimab/Balstilimab Combo Fails Primary Endpoint in Phase II Gastroesophageal Cancer Study
AGEN has more than doubled off its 52-week low of $1.6.
Summary
Agenus Inc. reported Phase II clinical trial data for its botensilimab, balstilimab, and Agent-797 combination therapy in PD-1 refractory gastroesophageal cancer. Crucially, the study did not meet its primary endpoint of objective response rate, which is a significant setback for the company's drug development pipeline. While the data did demonstrate immune reprogramming and durable survival, the failure to meet the primary endpoint is the overriding factor for investors. This news is particularly impactful given the company's recent 10-K filing, which disclosed substantial doubt about its ability to continue as a going concern. The miss on a key clinical milestone will likely raise further concerns about the company's financial viability and future prospects, potentially leading to significant stock price volatility. Investors will now watch for the company's next steps regarding this program and any potential impact on its financial runway.
At the time of this announcement, AGEN was trading at $4.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $183.9M. The 52-week trading range was $1.60 to $7.34. This news item was assessed with negative market sentiment and an importance score of 9 out of 10. Source: Reuters.